Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma.
S. A. Visaga, H. Kalonia, V. Verma, S. Sinha, S. K. Singh, S. Upadhyay, S. Sahdev, A. Pansari, R. Kumar, M. Bandgar, N. Karanjule, R. K. Shirumalla, K. Morishita, R. Tandon
The paper develops selective FPR2 agonists and shows they reduce non-resolving inflammation in asthma models.
bioRxiv · Sep 16, 2021 · PreprintPharmacology & Toxicology